{"id":"baricitinib-treatment","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Increased risk of thrombocytopenia"},{"rate":"null","effect":"Increased risk of liver enzyme elevations"}]},"_chembl":{"chemblId":"CHEMBL2105759","moleculeType":"Small molecule","molecularWeight":"371.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting JAK enzymes, baricitinib reduces the production of pro-inflammatory cytokines, leading to decreased inflammation. This mechanism is particularly useful in treating autoimmune diseases such as rheumatoid arthritis.","oneSentence":"Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a role in inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:29.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT07262983","phase":"PHASE1","title":"Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES","enrollment":20},{"nctId":"NCT06631287","phase":"PHASE3","title":"Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","status":"RECRUITING","sponsor":"Wes Ely","startDate":"2024-10-21","conditions":"Long COVID, Sars-CoV-2 Infection, Coronavirus Infections","enrollment":550},{"nctId":"NCT07491016","phase":"","title":"Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2026-03-01","conditions":"Telitacicept, Treatment Compliance, Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT05524311","phase":"PHASE2","title":"Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-10","conditions":"Juvenile Dermatomyositis","enrollment":16},{"nctId":"NCT06158113","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-03-13","conditions":"Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus","enrollment":10},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT05016297","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Sjogren's Syndrome","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-14","conditions":"Sjogren's Syndrome","enrollment":87},{"nctId":"NCT07448363","phase":"","title":"Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)","enrollment":50},{"nctId":"NCT07449910","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2026-03-17","conditions":"Acute Ichemic Stroke, Anterior Cerebral Artery Stroke, Baricitinib","enrollment":750},{"nctId":"NCT06923072","phase":"PHASE2","title":"Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2026-02-18","conditions":"Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease","enrollment":12},{"nctId":"NCT07028385","phase":"PHASE2","title":"Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-09-22","conditions":"HIV","enrollment":30},{"nctId":"NCT07209267","phase":"PHASE2","title":"Baricitinib Curative Repression of HIV-1","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"HIV Infection, HIV","enrollment":20},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT05651880","phase":"PHASE3","title":"Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03","conditions":"Active Non-anterior Non-infectious Uveitis","enrollment":33},{"nctId":"NCT06868381","phase":"PHASE2","title":"A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-04-01","conditions":"Cardiac Sarcoidosis","enrollment":10},{"nctId":"NCT06240351","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-04-22","conditions":"Frontal Fibrosing Alopecia","enrollment":15},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT07357649","phase":"PHASE4","title":"Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-01","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT05189106","phase":"PHASE1, PHASE2","title":"Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2022-12-05","conditions":"Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment","enrollment":17},{"nctId":"NCT03921554","phase":"PHASE2","title":"JAK Inhibitor Treatment in AGS","status":"COMPLETED","sponsor":"Adeline Vanderver, MD","startDate":"2019-06-03","conditions":"Aicardi Goutieres Syndrome","enrollment":54},{"nctId":"NCT06490757","phase":"PHASE2","title":"A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-02","conditions":"Inflammatory Hepatocellular Adenoma","enrollment":25},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT07003997","phase":"PHASE2","title":"JAK Signaling in Depression","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-03","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT06737705","phase":"PHASE2","title":"Baricitinib for Respiratory Injury in Patients With Intracerebral Hemorrhage","status":"COMPLETED","sponsor":"De-zhi Kang","startDate":"2025-01-01","conditions":"Intracerebral Hemorrhage, Acute Lung Injury(ALI)","enrollment":110},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT07081763","phase":"PHASE2","title":"Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2026-05","conditions":"HIV-1-infection","enrollment":191},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT06065046","phase":"PHASE2","title":"Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-24","conditions":"Traumatic Brain Injury","enrollment":100},{"nctId":"NCT05849038","phase":"PHASE2","title":"Inflammation and Depression in People With HIV","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-12-11","conditions":"HIV, Depression, Anhedonia","enrollment":60},{"nctId":"NCT06977035","phase":"NA","title":"Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-05","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT04901325","phase":"PHASE2","title":"Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2023-10-03","conditions":"Pyoderma Gangrenosum, Skin Diseases, Wound Heal","enrollment":5},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT03549416","phase":"","title":"BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2018-01-01","conditions":"Atopic Dermatitis","enrollment":1200},{"nctId":"NCT06898372","phase":"","title":"Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome","status":"COMPLETED","sponsor":"IRCCS Fondazione Stella Maris","startDate":"2024-04-07","conditions":"Aicardi-Goutières Syndrome (AGS)","enrollment":24},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT05099315","phase":"","title":"Microbiome in Atopic Dermatitis Under Systemic Therapy","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2019-10-01","conditions":"Atopic Dermatitis","enrollment":600},{"nctId":"NCT06797310","phase":"PHASE2","title":"Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-01-23","conditions":"Alopecia Areata","enrollment":30},{"nctId":"NCT01724580","phase":"","title":"Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes","status":"APPROVED_FOR_MARKETING","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)","enrollment":""},{"nctId":"NCT06768294","phase":"PHASE2","title":"Baricitinib in CPPD - the BAPTIST Study","status":"NOT_YET_RECRUITING","sponsor":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","startDate":"2025-01","conditions":"Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis","enrollment":32},{"nctId":"NCT06768840","phase":"PHASE2, PHASE3","title":"Vitiligo, New Treatment and Serum s100B","status":"RECRUITING","sponsor":"South Valley University","startDate":"2024-10-02","conditions":"Vitiligo, Generalized","enrollment":50},{"nctId":"NCT04084223","phase":"NA","title":"JAKPOT (JAK Inhibitors and Predictors of Outcome in RheumaToid Arthritis)","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2019-10-10","conditions":"Rheumatoid Arthritis","enrollment":51},{"nctId":"NCT04774224","phase":"PHASE2","title":"Baricitinib in New-onset Type 1 Diabetes","status":"COMPLETED","sponsor":"St Vincent's Institute of Medical Research","startDate":"2020-10-30","conditions":"Type 1 Diabetes","enrollment":91},{"nctId":"NCT06687551","phase":"PHASE4","title":"JAK Inhibitor Dose TAPering Strategy Study","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2025-01-01","conditions":"Rhumatoid Arthisis","enrollment":308},{"nctId":"NCT06662721","phase":"PHASE2","title":"Baricitinib for Refractory Takayasu Arteritis","status":"COMPLETED","sponsor":"Liu Tian","startDate":"2023-04-03","conditions":"Takayasu Arteritis","enrollment":10},{"nctId":"NCT02759731","phase":"PHASE1, PHASE2","title":"Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-11-01","conditions":"Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease","enrollment":24},{"nctId":"NCT05638932","phase":"","title":"Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments","status":"COMPLETED","sponsor":"Aetion, Inc.","startDate":"2020-06-16","conditions":"COVID-19","enrollment":1442},{"nctId":"NCT03334435","phase":"PHASE3","title":"A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-28","conditions":"Atopic Dermatitis","enrollment":1645},{"nctId":"NCT06573593","phase":"","title":"Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-07-29","conditions":"Alopecia Areata, Janus Kinase Inhibitors","enrollment":150},{"nctId":"NCT06558305","phase":"","title":"IL-6, IL-12, IL-15 and IL-23 Expression Levels in Rheumatoid Arthritis Patients","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-09","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT06548802","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-02-29","conditions":"Pulmonary Injury After Intracerebral Hemorrhage","enrollment":100},{"nctId":"NCT06545110","phase":"PHASE1","title":"Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib","status":"ACTIVE_NOT_RECRUITING","sponsor":"South Valley University","startDate":"2023-09-01","conditions":"Alopecia Areata","enrollment":120},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05188521","phase":"PHASE2","title":"Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus","status":"COMPLETED","sponsor":"Aaron R. Mangold","startDate":"2022-01-11","conditions":"Cutaneous Lichen Planus","enrollment":12},{"nctId":"NCT06439615","phase":"PHASE2","title":"Baricitinib for the Lung Injury Following Spontaneous SAH","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-08-01","conditions":"Spontaneous Subarachnoid Hemorrhage","enrollment":100},{"nctId":"NCT05003310","phase":"NA","title":"ConsideRAte Study - Splenic Stimulation for RA","status":"RECRUITING","sponsor":"Galvani Bioelectronics","startDate":"2021-10-19","conditions":"Rheumatoid Arthritis","enrollment":28},{"nctId":"NCT03670069","phase":"PHASE1","title":"Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-09-30","conditions":"Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma","enrollment":27},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT06366932","phase":"PHASE4","title":"Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models","status":"RECRUITING","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2023-09-25","conditions":"Atopic Dermatitis","enrollment":150},{"nctId":"NCT04890626","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19","status":"COMPLETED","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2020-04-04","conditions":"SARS-CoV-2 Infection","enrollment":356},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT06114407","phase":"PHASE2","title":"Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-10-30","conditions":"Spondyloarthritis, Axial","enrollment":184},{"nctId":"NCT03945760","phase":"EARLY_PHASE1","title":"Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects","status":"COMPLETED","sponsor":"Wright State Physicians","startDate":"2020-09-14","conditions":"Allergic Contact Dermatitis","enrollment":23},{"nctId":"NCT04027101","phase":"PHASE2","title":"BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2020-12-01","conditions":"Polymyalgia Rheumatic (PMR)","enrollment":34},{"nctId":"NCT05238896","phase":"PHASE4","title":"BARIcitinib Cognitive Emotional and Neural signaTuRE","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-27","conditions":"Rheumatoid Arthritis","enrollment":5},{"nctId":"NCT05660655","phase":"PHASE4","title":"Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2022-10-01","conditions":"Rheumatoid Arthritis","enrollment":94},{"nctId":"NCT05263505","phase":"PHASE2","title":"Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2022-02-21","conditions":"Mucous Membrane Pemphigoid, Cicatrizing Conjunctivitis","enrollment":2},{"nctId":"NCT04208464","phase":"PHASE2","title":"JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM","status":"COMPLETED","sponsor":"University of Manchester","startDate":"2021-10-07","conditions":"Idiopathic Inflammatory Myopathies","enrollment":15},{"nctId":"NCT04321993","phase":"PHASE2","title":"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","status":"UNKNOWN","sponsor":"Lisa Barrett","startDate":"2020-04-17","conditions":"COVID-19","enrollment":363},{"nctId":"NCT05361109","phase":"PHASE2","title":"Baricitinib for Cutaneous Dermatomyositis","status":"WITHDRAWN","sponsor":"University of Washington","startDate":"2022-06-01","conditions":"Dermatomyositis","enrollment":""},{"nctId":"NCT05950542","phase":"","title":"Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-09-10","conditions":"Vitiligo, Generalized","enrollment":30},{"nctId":"NCT05932524","phase":"PHASE2","title":"Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-07-07","conditions":"Immune Thrombocytopenia","enrollment":132},{"nctId":"NCT05914584","phase":"PHASE2, PHASE3","title":"\"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.","status":"UNKNOWN","sponsor":"Nantes University Hospital","startDate":"2023-07-01","conditions":"Hospital-acquired Pneumonia","enrollment":450},{"nctId":"NCT04822584","phase":"PHASE2","title":"Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-16","conditions":"Vitiligo","enrollment":49},{"nctId":"NCT05852847","phase":"PHASE2","title":"Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-05-16","conditions":"Immune Thrombocytopenia","enrollment":216},{"nctId":"NCT05827497","phase":"PHASE4","title":"Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-04-01","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT05187793","phase":"PHASE3","title":"Study of Efficacy of Different Treatment Regimens of Olokizumab","status":"UNKNOWN","sponsor":"R-Pharm","startDate":"2021-07-08","conditions":"COVID-19","enrollment":198},{"nctId":"NCT05674695","phase":"","title":"Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy","status":"RECRUITING","sponsor":"Fundación Academia Española de Dermatología","startDate":"2019-01-01","conditions":"Dermatitis, Atopic","enrollment":2500},{"nctId":"NCT05432531","phase":"PHASE3","title":"Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-06-01","conditions":"Lupus Nephritis","enrollment":60},{"nctId":"NCT05400889","phase":"PHASE2","title":"Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-06-10","conditions":"Idiopathic Inflammatory Myopathies","enrollment":10},{"nctId":"NCT05446831","phase":"PHASE2","title":"Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-07-13","conditions":"ITP, Immune Thrombocytopenia","enrollment":35},{"nctId":"NCT04640168","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1010},{"nctId":"NCT03440892","phase":"","title":"Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2017-11-01","conditions":"Rheumatoid Arthritis","enrollment":2500},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT01885078","phase":"PHASE3","title":"An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06-27","conditions":"Rheumatoid Arthritis","enrollment":2877},{"nctId":"NCT05302947","phase":"","title":"COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-02-01","conditions":"COVID-19, Mild to Moderate","enrollment":154},{"nctId":"NCT03026504","phase":"PHASE2","title":"Baricitinib in Relapsing Giant Cell Arteritis","status":"COMPLETED","sponsor":"Matthew J Koster","startDate":"2017-03-09","conditions":"Arteritis, Giant Cell","enrollment":15},{"nctId":"NCT05279391","phase":"NA","title":"Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","status":"UNKNOWN","sponsor":"Democritus University of Thrace","startDate":"2020-10-25","conditions":"COVID-19 Severe Respiratory Failure","enrollment":150},{"nctId":"NCT04401579","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 2 (ACTT-2)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-05-08","conditions":"COVID-19","enrollment":1033},{"nctId":"NCT05078294","phase":"","title":"Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2021-08-01","conditions":"Dermatitis, Atopic","enrollment":300},{"nctId":"NCT03755466","phase":"PHASE2","title":"Examination of Efficacy and Safety of Baricitinib in RA Patients","status":"UNKNOWN","sponsor":"Shinshu University","startDate":"2018-11-21","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT05006768","phase":"PHASE1","title":"Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2021-05-05","conditions":"Healthy","enrollment":30},{"nctId":"NCT04346147","phase":"PHASE2","title":"Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","status":"UNKNOWN","sponsor":"Hospital Universitario de Fuenlabrada","startDate":"2020-05-07","conditions":"COVID-19 Pneumonia","enrollment":168},{"nctId":"NCT04362943","phase":"","title":"Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults","status":"COMPLETED","sponsor":"Complejo Hospitalario Universitario de Albacete","startDate":"2020-04-20","conditions":"COVID-19","enrollment":576},{"nctId":"NCT04373044","phase":"PHASE2","title":"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2020-05-01","conditions":"Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":6},{"nctId":"NCT04340232","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Baricitinib for COVID-19","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2021-03","conditions":"COVID-19","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"baricitinib treatment","genericName":"baricitinib treatment","companyName":"University Hospital, Bordeaux","companyId":"university-hospital-bordeaux","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a role in inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}